Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of midostaurin plus standard chemotherapy and post-consolidation monotherapy in pediatric FLT3-mutated AML
jRCT2080224613Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2019
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of midostaurin in acute myeloid leukemia (AML), sponsored by Novartis. Started Mar 2019; status: completed.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2080224613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224613.